(VIANEWS) – Live Nation Entertainment (LYV), United Therapeutics Corporation (UTHR), Great Elm Capital Corp. (GECC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Live Nation Entertainment (LYV)
24.5% sales growth and 58.68% return on equity
Live Nation Entertainment, Inc. operates as a live entertainment company worldwide. It operates through Concerts, Ticketing, and Sponsorship & Advertising segments. The Concerts segment promotes live music events in its owned or operated venues, and in rented third-party venues. This segment operates and manages music venues; produces music festivals; creates and streams associated content; and offers management and other services to artists. The Ticketing segment manages the ticketing operations, including the provision of ticketing software and services to clients and consumers with marketplace for tickets and event information through mobile apps, other websites, retail outlets, and its primary websites, such as livenation.com and ticketmaster.com; and provides ticket resale services. This segment sells tickets for its events and third-party clients in various live event categories. This segment offers ticketing services for arenas, stadiums, amphitheaters, music clubs, concert promoters, professional sports franchises and leagues, college sports teams, performing arts venues, museums, and theaters. The Sponsorship & Advertising segment sells international, national, and local sponsorships and placement of advertising, including signage, online, and promotional programs; rich media offering that comprises advertising related with live streaming and music-related content; and ads across its distribution network of venues, events, and websites. This segment also manages the development of strategic sponsorship programs, as well as develops, books, and produces custom events or programs for specific brands. It owns, operates, or leases entertainment venues. The company was formerly known as Live Nation, Inc. and changed its name to Live Nation Entertainment, Inc. in January 2010. Live Nation Entertainment, Inc. was incorporated in 2005 and is headquartered in Beverly Hills, California.
Earnings Per Share
As for profitability, Live Nation Entertainment has a trailing twelve months EPS of $1.37.
PE Ratio
Live Nation Entertainment has a trailing twelve months price to earnings ratio of 73.75. Meaning, the purchaser of the share is investing $73.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 58.68%.
Yearly Top and Bottom Value
Live Nation Entertainment’s stock is valued at $101.04 at 11:22 EST, under its 52-week high of $107.24 and way higher than its 52-week low of $76.48.
Volume
Today’s last reported volume for Live Nation Entertainment is 1171820 which is 47.21% below its average volume of 2220090.
2. United Therapeutics Corporation (UTHR)
15.1% sales growth and 20.08% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $21.12.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 12.99. Meaning, the purchaser of the share is investing $12.99 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.08%.
Volume
Today’s last reported volume for United Therapeutics Corporation is 329299 which is 37.98% below its average volume of 531040.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 19.8% and 19.3%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 33.7%, now sitting on 2.5B for the twelve trailing months.
Sales Growth
United Therapeutics Corporation’s sales growth for the next quarter is 15.1%.
3. Great Elm Capital Corp. (GECC)
12.4% sales growth and 15.99% return on equity
Great Elm Capital Corporation is a business development company which specializes in loan and mezzanine, middle market investments. The fund prefers to invest in media, commercial services and supplies, healthcare, telecommunication services, communications equipment. It typically makes equity investments between $3 million and $10 million in companies with revenues between $3 million and $75 million.
Earnings Per Share
As for profitability, Great Elm Capital Corp. has a trailing twelve months EPS of $2.18.
PE Ratio
Great Elm Capital Corp. has a trailing twelve months price to earnings ratio of 4.68. Meaning, the purchaser of the share is investing $4.68 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.99%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.9%, now sitting on 36.32M for the twelve trailing months.
Moving Average
Great Elm Capital Corp.’s value is under its 50-day moving average of $10.41 and higher than its 200-day moving average of $10.19.
Volume
Today’s last reported volume for Great Elm Capital Corp. is 36407 which is 109.64% above its average volume of 17366.
4. Erie Indemnity Company (ERIE)
11.9% sales growth and 30.15% return on equity
Erie Indemnity Company operates as a managing attorney-in-fact for the subscribers at the Erie Insurance Exchange in the United States. The company provides sales, underwriting, policy issuance, and renewal services for the policyholders on behalf of the Erie Insurance Exchange. It also offers sales related services, including agent compensation, and sales and advertising support services; and underwriting services comprise underwriting and policy processing; and other services consist of customer services and administrative support services, as well as information technology services. Erie Indemnity Company was incorporated in 1925 and is based in Erie, Pennsylvania.
Earnings Per Share
As for profitability, Erie Indemnity Company has a trailing twelve months EPS of $9.28.
PE Ratio
Erie Indemnity Company has a trailing twelve months price to earnings ratio of 42.55. Meaning, the purchaser of the share is investing $42.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.15%.
Yearly Top and Bottom Value
Erie Indemnity Company’s stock is valued at $394.87 at 11:22 EST, under its 52-week high of $420.34 and way above its 52-week low of $199.49.
Sales Growth
Erie Indemnity Company’s sales growth is 11.2% for the present quarter and 11.9% for the next.
5. Upwork (UPWK)
10.9% sales growth and 15.1% return on equity
Upwork Inc., together with its subsidiaries, operates a work marketplace that connects businesses with various independent professionals and agencies in the United States, India, the Philippines, and internationally. The company's work marketplace provides access to talent with various skills across a range of categories, including administrative support, sales and marketing, design and creative, and customer service, as well as web, mobile, and software development. Its work marketplace also enables clients to streamline workflows, such as talent sourcing, outreach, and contracting. The company's work marketplace offers access to various functionalities for remote engagements with talent, including communication and collaboration, ability to receive talent invoices through their work marketplace, and payment protection. Its marketplace offerings include Upwork Payroll and Upwork Enterprise, as well as managed and escrow services. The company was formerly known as Elance-oDesk, Inc. and changed its name to Upwork Inc. in May 2015. Upwork Inc. was incorporated in 2013 and is headquartered in San Francisco, California.
Earnings Per Share
As for profitability, Upwork has a trailing twelve months EPS of $0.06.
PE Ratio
Upwork has a trailing twelve months price to earnings ratio of 193.83. Meaning, the purchaser of the share is investing $193.83 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.1%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.7%, now sitting on 719.21M for the twelve trailing months.
